Core provides infrastructure, disease modelling and compound screening expertise, to facilitate translation of basic scientific discoveries into tangible hit drug candidates. Platform acts as interface between fundamental biomedical research and high-standard drug discovery.

Assist researchers in the development
and analysis of various in vivo neurodegenerative and cancer models including humanized
and germ-free animals. The facility has the capacity to house different transgenic and
germ-free mouse strains in more than 2500 IVC cages within a SOPF breeding barrier
for researchers from academia as well as for industrial partner

The genomics platform at the LCSB started at the end of 2016, and offers next-generation sequencing, single cell sequencing services. The platform has currently two sequencers, a NextSeq2000 and a MiSeq from Illumina and a MinION nanopore sequencer from Oxford Nanopore Technologies. The Illumina sequencers allow sequencing tunable read lengths up to 300 bases of single- as well as paired-end runs while the MinION sequencer complements by ultra-long read lengths (up to several hundreds of kilobases). Together this offers high flexibility for the different sequencing needs. The platform offers full service, starting with advice in experimental design up to sequencing data generation. Besides the wide range of standard services, the platform also offers new method development. In addition to next generation sequencing services platform also offers single cell processing and sequencing, digital PCR and genotyping by sequencing services.

The Metabolomics and Lipidomics Platform facilitates metabolism-related research, serving researchers from academia to industry in Luxembourg and beyond. We specialize in the analysis of small molecules within complex biological matrices. Our state-of-the-art analytical infrastructure and broad method portfolio accelerate scientific discoveries in the areas of biology and biomedicine.